Metropolitan Life Insurance CO Castle Biosciences Inc Transaction History

Metropolitan Life Insurance CO

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Mar 30, 2023	SELL	$33.17 - $46.98 $151,421 - $214,463	-4,565 Reduced 76.4%	1,410 $63,000
Q1 2022 May 12, 2022	SELL	$33.17 - $46.98 $151,421 - $214,463	-4,565 Reduced 76.4%	1,410 $63,000
Q4 2021 Jun 21, 2023	BUY	$39.06 - $67.58 $178,308 - $308,502	4,565 Added 323.76%	5,975 $256,000
Q3 2021 Jun 21, 2023	BUY	$60.13 - $77.6 $274,493 - $354,244	4,565 Added 323.76%	5,975 $397,000
Q2 2021 Jun 21, 2023	BUY	$50.07 - $76.78 $228,569 - $350,500	4,565 Added 323.76%	5,975 $438,000
Q2 2021 Mar 30, 2023	BUY	$50.07 - $76.78 $87,522 - $134,211	1,748 Added 41.35%	5,975 $438,000
Q2 2021 Aug 16, 2021	BUY	$50.07 - $76.78 $298,967 - $458,453	5,971 Added 149275.0%	5,975 $438,000
Q1 2021 Jun 26, 2023	BUY	$58.92 - $97.33 $165,977 - $274,178	2,817 Added 199.79%	4,227 $289 Million
Q1 2021 Mar 30, 2023	BUY	$58.92 - $97.33 $57,034 - $94,215	968 Added 29.7%	4,227 $289,000
Q1 2021 May 14, 2021	SELL	$58.92 - $97.33 $191,784 - $316,809	-3,255 Reduced 99.88%	4 $289,000
Q4 2020 Jun 22, 2023	BUY	$43.6 - $73.05 $80,616 - $135,069	1,849 Added 131.13%	3,259 $218,000
Q3 2020 Jun 26, 2023	BUY	$38.47 - $52.03 $71,131 - $96,203	1,849 Added 131.13%	3,259 $167,000
Q2 2020 Jun 26, 2023	BUY	$27.28 - $43.01 $50,440 - $79,525	1,849 Added 131.13%	3,259 $122,000
Q1 2020 Jul 12, 2023	BUY	$23.08 - $35.53 $42,674 - $65,694	1,849 Added 131.13%	3,259 $97,000
Q1 2020 Mar 30, 2023	BUY	$23.08 - $35.53 $42,674 - $65,694	1,849 Added 131.13%	3,259 $97,000
Q1 2020 May 15, 2020	BUY	$23.08 - $35.53 $75,217 - $115,792	3,259 New	3,259 $97,000

201

24.5M

303K

30.3K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $724M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.